Patents Examined by Dameron L. Jones
  • Cytostatic lanthanum compounds
    Patent number: 7122643
    Abstract: Lanthanum compounds are provided having general formulas (I) Rni+Yin? and (II) Rb+Yb? which may be used as medicaments in the prophylaxis and/or treatment of cancer diseases.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: October 17, 2006
    Assignee: Faustus Forschungs Cie. Translational Cancer Research GmbH
    Inventor: Bernhard Keppler
  • Methods and compositions for targeted drug delivery
    Patent number: 7122172
    Abstract: Disclosed are Drug Delivery Molecules (DDMs) which both facilitate functional imaging, as by PET or SPECT, and create a biological effect and methods of their use. These DDMs are variously designed to target specific receptors, then become internalized and then function biologically, as for purposes of cell destruction or therapy.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: October 17, 2006
    Inventor: Gerhart Graupner
  • Quinoline derivative as diagnostic probe for disease with tau protein accumulation
    Patent number: 7118730
    Abstract: The present invention provides compounds, or salts or solvates thereof, which can be used as probes for the imaging diagnosis of diseases in which tau protein accumulates, and compositions and kits comprising such compounds, or salts or solvates thereof. The present invention also provides a method for staining neurofibrillary tangles in brain samples, and a pharmaceutical composition for the treatment and/or prophylaxis of a disease in which ?-sheet structure is the cause or possible cause.
    Type: Grant
    Filed: November 28, 2003
    Date of Patent: October 10, 2006
    Assignee: BF Research Institute, Inc.
    Inventors: Yukitsuka Kudo, Masako Suzuki, Takahiro Suemoto, Nobuyuki Okamura, Tsuyoshi Shiomitsu, Hiroshi Shimazu
  • Drugs for the diagnosis of tissue reproductive activity or the treatment of proliferative diseases
    Patent number: 7118731
    Abstract: An agent which comprises, as an active ingredient, a radiolabeled compound as represented by the following formula or a pharmaceutically acceptable salt thereof: wherein R1 denotes hydrogen, or a linear- or branched-chain alkyl group having 1–8 carbon atoms, R2 denotes hydrogen, hydroxyl or a halogen substituent, R3 denotes hydrogen or fluorine substituent, R4 denotes oxygen, sulfur, or a methylene substituent, and R5 denotes a radioactive halogen substituent. The agent is stable in vivo, and either stays in cells or is incorporated in DNA, thus serving for diagnosis of tissue proliferation activity or treatment of proliferative disease.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: October 10, 2006
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Jun Toyohara, Akio Hayashi
  • Therapeutic and diagnostic compounds, compositions, and methods
    Patent number: 7115720
    Abstract: The invention provides a complex comprising a) a compound formula I: wherein R1, X and n have any of the values described in the specification, or a pharmaceutically acceptable salt thereof; and b) a radionuclide. The complexes are useful as diagnostic agents and as therapeutic agents. The invention also provides methods and intermediates useful for preparing the complexes of the invention, as well as therapeutic and diagnostic methods.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: October 3, 2006
    Assignee: Neorx Corporation
    Inventor: Alan R. Fritzberg
  • Method for exfoliating skin
    Patent number: 7115251
    Abstract: The present invention relates to an exfoliating composition. The composition comprises a mixture. The mixture comprises phenolsulfonic acid, guaiacolsulfonic acid, and optionally sulfosalicylic acid and citric acid.
    Type: Grant
    Filed: May 21, 2003
    Date of Patent: October 3, 2006
    Assignee: Northern Research Laboratories, Inc.
    Inventor: Michael Basara
  • Solid-phase electrophilic fluorination
    Patent number: 7115249
    Abstract: The invention relates to compounds of formula (I); wherein R1 and R2 independently selected from C1-6 alkyl; P1, P2, P3, and P4 are each independently hydrogen or a protecting group; and their use in the preparation of 18F-labelled 6-L-fluorodopa
    Type: Grant
    Filed: June 18, 2002
    Date of Patent: October 3, 2006
    Assignees: GE Healthcare Ltd., Hammersmith Imanet Ltd.
    Inventors: Sajinder Kaur Luthra, Frank Brady, Harry John Wadsworth
  • Radiolabeled annexins
    Patent number: 7115248
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: October 3, 2006
    Assignee: NeoRx Corporation
    Inventors: Sudhakar Kasina, John M Reno, Louis J Theodore
  • Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry
    Patent number: 7112319
    Abstract: The present invention relates to devices and methods of use thereof for making semiderivative voltammetric and chronoamperometric measurements of chemicals, e.g. neurotransmitters, precursors, and metabolites, in vitro, in vivo, or in situ. The invention relates to methods of diagnosing and/or treating a subject as having or being at risk of developing a disease or condition that is associated with abnormal levels of one or more neurotransmitters including, inter alia, epilepsy, diseases of the basal ganglia, athetoid, dystonic diseases, neoplasms, Parkinson's disease, brain injuries, spinal cord injuries, and cancer. The invention provides methods of differentiating white matter from grey matter using microvoltammetry. In some embodiments, regions of the brain to be resected or targeted for pharmaceutical therapy are identified using Broderick probes.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: September 26, 2006
    Assignees: The Research Foundation of the City University of New York, New York University
    Inventors: Patricia A. Broderick, Steven V. Pacia
  • Non-invasive diagnostic imaging technology for mitochondria dysfunction using radiolabeled lipophilic salts
    Patent number: 7112318
    Abstract: The invention provides a series of lipophilic phosphonium cations (PhCs) labeled with 18F for non-invasive assessment of ??m, lipophilic ammonium cation analogs of the PhCs, and methods of using same for imaging and detection of mitochondrial-related pathologies in patients using PET or SPECT.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: September 26, 2006
    Assignee: The Johns Hopkins University
    Inventors: Igal Madar, Hayden T. Ravert, Robert Francis Dannals, Ursula A. Scheffel, James J. Frost
  • Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents
    Patent number: 7108845
    Abstract: There is provided a method of synthesis of a radiolabelled platinum chemotherapeutic agent comprising the steps of: converting a metal halide to a radiolabelled platinum halide wherein the radiolabel is a radioisotope of Pt; and synthesizing the radiolabelled platinum chemotherapeutic agent from the radiolabelled platinum halide.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: September 19, 2006
    Assignee: Australian Nuclear Science & Technology Organisation
    Inventor: Suzanne V. Smith
  • Oxygen delivery agents and uses for the same
    Patent number: 7105151
    Abstract: The present invention describes, inter alia, oxygen delivery agents or blood substitutes comprising a fluorinated gas and a stabilizing material, uses for the oxygen delivery agents or blood substitutes, and apparatus for making and delivering the oxygen delivery agents or blood substitutes.
    Type: Grant
    Filed: January 6, 2003
    Date of Patent: September 12, 2006
    Assignee: ImaRx Therapeutics, Inc.
    Inventors: Evan C. Unger, Thomas McCreery, Yunqiu Wu
  • Liposome containing hydrophobic iodine compound
    Patent number: 7101532
    Abstract: A liposome containing a hydrophobic iodine compound such as a 1,3,5-triiodobenzene derivative having at least one substituent containing 18 or more carbon atoms as a membrane component, and an X-ray contrast medium containing the liposome for use in radiography of a vascular disease and the like.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: September 5, 2006
    Assignee: Fuji Photo Film Co., Ltd.
    Inventors: Kazuhiro Aikawa, Hiroshi Kitaguchi
  • Tuftsin metallopeptide analogs and uses thereof
    Patent number: 7097824
    Abstract: Tuftsin receptor-specific peptides, peptidomimetics and peptide-like constructs are provided, particularly for use in biological, pharmaceutical and radiopharmaceutical applications, in which the peptide, peptidomimetic or construct is conformationally fixed on complexation of the metal ion-binding portion thereof with a metal ion, resulting in a peptide, peptidomimetic or construct with increased affinity for the tuftsin receptor.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: August 29, 2006
    Assignee: Palatin Technologies, Inc.
    Inventor: Shubh D. Sharma
  • High dose radionuclide complexes for bone marrow suppression
    Patent number: 7097823
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: August 29, 2006
    Assignee: NEORX Corporation
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Skeletal-targeted radiation to treat bone-associated pathologies
    Patent number: 7094885
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: August 22, 2006
    Assignee: NeoRx Corporation
    Inventor: Alan R. Fritzberg
  • Imaging probes
    Patent number: 7090829
    Abstract: The present invention relates to fluorinated and paramagnetic polyuronides (Formulas I–IV) and proteins useful as imaging probes, diagnostic agents and contrast agents. Additionally, the present invention relates to imaging methods employing the present compounds of Formulas I–IV.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: August 15, 2006
    Assignee: CarboMer, Inc.
    Inventor: Manssur Yalpani
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 7090828
    Abstract: The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: August 15, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Edward H. Cheesman, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye, Michael Sworin
  • Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
    Patent number: 7087212
    Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: August 8, 2006
    Assignee: Mallinckrodt, Inc
    Inventors: Gary L. Cantrell, B. Daniel Burleigh
  • Ultrasound contrast agents and methods of making and using them
    Patent number: 7083778
    Abstract: Gas or air filled microbubble suspensions in aqueous phases usable as imaging contrast agents in ultrasonic echography. They contain surfactants and, optionally, hydrophilic stabilizers. The surfactants can be in the form of liposomes. The suspensions are obtained by exposing the surfactants to air or a gas before or after admixing with an aqueous phase. One can impart outstanding resistance against collapse under pressure to these gas-filled microbubbles used as contrast agents in ultrasonic echography by using as fillers gases whose solubility in water, expressed in liter of gas by liter of water under standard conditions, divided by the square root of the molecular weight does not exceed 0.003. Contrast agents with particular mixtures of gases are also disclosed that have advantageous properties.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: August 1, 2006
    Assignee: Bracco International B.V.
    Inventors: Michel Schneider, Feng Yan, Nadine Garcel, legal representative, Jerome Puginier, Marie-Bernadette Barrau, Philippe Bussat, Eva Hybl, Daniel Bichon, Pascal Grenier, deceased